F FDA (Food and Drug Administration), 1–11, 13, 27–29, 33, 65–66, 68, 70–72, 82–87, 89–91, 93–95, 98–104, 106–9, 116–17, 120–21, 124–29, 152–59, 165–67, 173–74, 182, 186 Financial toxicity, 135, 137, 141, 186, 193 Food insecurity, 44, 135 G Genetic mutations, 30, 32, 56, 61, 69, 73, 77, 83, 91, 98, 191–92 Genome, 29–30, 34–36, 69, 162, 170, 179–80, 186 Glioblastoma, 8, 104, 148, 186, 194 H Health equity, 17, 63–64, 161, 166–67 Hematologic cancers, 1, 6–7, 91, 94, 99, 120, 124, 142, 194 HIV (Human Immunodeficiency Virus), 22, 48, 50–51, 135, 187, 194 Hodgkin lymphoma, 16, 48, 94, 106, 135, 187 HPV (Human Papillomavirus), 21, 38, 48–50, 56, 60, 64, 172, 182, 185, 187, 194 Human papillomavirus, 21, 38, 48–50, 185, 187, 194 I ICIs (Immune checkpoint inhibitors), 1, 6, 10, 14, 93, 99–103, 106–9, 125–30, 133, 144, 147–48, 194 Imaging, 54, 80, 82, 146, 149, 157, 184, 188–89 Immune cells, 33–35, 99, 101–2, 104, 106, 108–9, 117, 120–21, 124–26, 129–30, 149–50, 184–85, 189–90 Immune checkpoint inhibitors, 1, 6, 10, 14, 77, 99–102, 106, 108, 113, 127, 187, 192, 194 Immune system, 1, 4, 6–7, 24–26, 32–35, 48, 99–101, 105, 107, 109, 116–17, 124–25, 129–30, 184–85, 187 Immunotherapeutics, 1, 6–7, 10, 14, 94, 99–102, 107, 116–17, 120–21, 124–27, 129–31, 148, 150 Immunotherapy, 6–7, 34–35, 76–78, 83–84, 93, 99–109, 111, 113–17, 119–21, 123–31, 133, 148–51, 157–58, 165–66, 185, 187 Isabella Fraser, 7, 87, 108, 110 JJackie Vanraaphorst, 6, 86, 88 James P. Allison, PhD, 103 L Lesa Kirkman, 7, 118, 120 Leukemia, 12, 16, 26, 36, 40, 115–16, 121, 124, 165, 184, 187, 192, 194 Liquid biopsy, 5, 11, 65–67, 144, 166, 194 Liver cancer, 6, 20, 22, 38, 42, 49–50, 77, 106, 108 Lung cancer, 14, 20, 22, 26–27, 38–40, 51, 55–56, 59–61, 76–79, 83–85, 104, 107–9, 135, 188, 192 Lung cancer screening, 5, 55, 58–59, 61, 63, 78, 194 Lymphedema, 77, 134 Lymph nodes, 26, 33–34, 77, 95, 107, 187 Lynch syndrome, 31, 61, 146, 187, 191 M Machine learning, 65–66, 69, 147, 174, 187, 194 Mammogram, 54, 60–61, 188, 194 Medical research, 1–3, 8, 11, 22–24, 32, 35, 68–70, 146, 152–54, 156, 163, 166–67, 169 Melanoma, 12, 16, 20, 47, 51, 102–3, 106, 108–9, 130, 133, 147, 188, 194 Metastatic cancers, 8, 14, 34, 43, 107, 133–34, 147 Microbiome, 35–36, 69, 105, 150–51, 188, 194 microbiome in Cancer Treatment, 35, 131, 138, 150 Multiple myeloma, 7, 42, 52, 116, 120–21, 123–24, 127, 184, 188, 192, 194 N NCI (National Cancer Institute), 1–4, 8–9, 15, 17–19, 23, 36, 90, 107–8, 152–55, 158–59, 163, 166–67, 169–72, 174–75, 178, 180–84, 188, 194 NHL (non-Hodgkin lymphoma), 11, 16, 18, 48, 50, 52, 95, 106, 116, 121, 187–88 Non-Hodgkin lymphoma, 11, 16, 18, 48, 50, 52, 95, 106, 187–88 O Obesity, 5, 10, 20–21, 38, 41–42, 44–45, 166, 171, 194 Older adults, 11, 17–18, 43, 76, 80, 132, 134, 138, 190 Ovarian cancer, 6, 10, 40, 42, 46, 74, 77–78, 86, 89, 184, 187, 191–92, 194 P Palliative care, 7, 138–39, 188, 194 Pancreatic cancer, 8, 20, 32, 40, 42, 77, 84, 128, 133, 143, 148–50 Patient care, 1, 8, 66, 68, 71, 75, 142–44, 146, 152–59, 161–63, 165–66, 168, 197 Patient navigation services, 8, 64, 141, 174, 194 patient navigators, 64, 132, 141, 189, 194 Patient reported outcomes. See PROs Patients, pediatric, 65, 91, 94, 108, 116, 136 Pediatric cancer, 124, 159, 162, 194 Physical activity, 7, 38, 42–44, 46, 108, 132, 138, 142, 147, 194 Pillars of cancer treatment, 6, 74, 76, 82, 194 Policymakers, 2, 8, 13, 144, 163, 166–67, 197 Precancerous lesions, 54–57, 65 Precision medicine, 4, 24, 35–36, 83, 86–87, 107, 150, 166, 189, 194 PROs (patient reported outcomes), 7–8, 70, 142, 146, 189, 194 Prostate cancer, 3, 5, 11–12, 18, 20, 51–53, 56, 60, 62, 65, 72–73, 82, 97–98, 189, 192 PSA (prostate-specific antigen), 56, 60, 82, 189, 194 PSMA, 82, 189, 194 Public health, 8, 12, 14, 25, 42, 58, 85, 172, 182, 185–86 R Racial and ethnic minorities, 1, 3, 6, 15, 17–19, 38, 44, 51, 62–63, 70, 75, 135, 137 Radiation therapy, 80–83, 105, 108, 131, 144, 149, 184, 188–89, 194 AACR Cancer Progress Report 2023 Index 194
RkJQdWJsaXNoZXIy NTkzMzk=